We inform you that Angelini Holding S.p.A. uses cookies (small files saved on your hard disk) to improve your browsing experience on this site. Angelini Holding S.p.A. uses third party cookies that allow third parties to access personal data collected during navigation. By continuing to browse the site, by accessing any area of it or selecting an element of it (for example, an image or a link) you consent to the use of cookies. At the following link you will find our extended information on cookies with a description of the categories present and links to the information of third parties as independent data controllers and you will have the opportunity to decide which cookies to authorize or whether to deny consent to all or only some cookies CONTINUE

22 SEP 2020

Press Release

Angelini: five hundred thousand liters of Amuchina to schools

Agreement with the Extraordinary Commissioner for the Covid Emergency for the supply of the sanitizing gel, symbol of the fight against Coronavirus in everyday life.

 

Rome, 22 September – The Angelini Group has supplied 500,000 liters of Amuchina Xgerm – a total of almost one million bottles of gel – for the prevention and containment of Coronavirus in schools. The supply helps to ensure a significant proportion of the volumes of sanitizing gel needed at a national level. The agreement is part of the plan coordinated by the Extraordinary Commissioner for Emergency Domenico Arcuri, in line with the provisions of the Ministry of Education.

With the reopening of schools, the constant and punctual distribution of personal protective equipment continues for us: even as regards sanitizing gel, the collaboration between institutions and private business is important and strategic, allowing students and school staff to have this important prevention tool available everyday” said Domenico Arcuri, Extraordinary Commissioner for the Coronavirus emergency.

Since last spring, we have been fully prepared to support Commissioner Arcuri’s structure, which we have supported with various projects. This agreement for the supply of Amuchina in schools is added to the supply of 25 high speed production lines for surgical masks, two of which - installed in our plants - have already produced 40 million protective devices. We are proud to contribute to the hygiene and deep disinfection of students, teachers and school staff on the eve of a very delicate academic year,” said Sergio Marullo di Condojanni, CEO of Angelini Holding. 

Amuchina Xgerm, produced by Angelini Pharma and now the symbol of the fight against Coronavirus in everyday life, will be distributed in 8000 schools. It is a huge production effort that once again involves the Ancora plant, where Angelini Pharma’s employees have never stopped producing up to 95,000 bottles a day, 9 million since the beginning of the pandemic.

I’m proud of the agreement signed by the Angelini Group. Amuchina confirms its character as an icon of hygiene, a constant and reassuring presence in people’s daily lives,” adds Pierluigi Antonelli, CEO of Angelini Pharma. “During 2020, Amuchina has responded to the expectations of the citizens from an environmental point of view, thanks to the certification of the product and the plants that produce it, and from a social point of view, with donations to the first affected Regions and to Civil Protection, in addition to the collaboration for price transparency. Today we are on the side of school, both with this supply and with a campaign dedicated to making young people aware of the correct hygiene and health standards”.

 

 

Amuchina 

Amuchina, produced by Angelini Pharma in technologically advanced sites, has UNI EN ISO 9001:2015 and UNI EN ISO 13485:2016 quality certifications and UNI EN ISO 14001:2015 environmental certification. Due to its particular formulation (with a percentage of ethyl alcohol equal to 74%), Amuchina Xgerm, unlike other gels on the market, is classified as a disinfectant and is a Surgical Medical Device. 

Throughout its history, Amuchina has been on the side of people in numerous health emergencies, such as the Tuberculosis epidemic (1939), the Cholera epidemic (1980), the Sars epidemic (2003), the H1N1 epidemic (2009), down to the current Coronavirus pandemic.

 

The Angelini Group

Angelini Holding is the parent company of the international Angelini group operating in the pharmaceutical and consumer goods sectors. Founded in Italy in 1919, the Angelini Group today operates in 17 countries with about 5,700 people and a turnover of 1.7 billion euros. In Pharma, Angelini Pharma specializes in the therapeutic areas of Mental Health (including Pain), Rare Diseases and Consumer Health. Angelini Pharma products are marketed in 70 countries around the world, both through direct presence and partnerships with local companies.

The Angelini group also operates in Personal Care with Fater, a 50/50 joint venture with Procter & Gamble, leader in the Italian market of personal care products and key player in the European market of household products. In the Machinery sector, again in joint venture with P&G, Fameccanica is an international automation and robotics group for the FMCG industry that develops high productivity systems and technologies, as well as high value-added digital services, with an approach that is continuously focused on sustainability. Angelini Beauty is the Business Unit dedicated to the Perfumery and Dermocosmetics sectors, through license agreements with both companies in the Fashion sector and proprietary brands. In the wine sector, Bertani Domains is active with six wineries, with a total of 1,700 hectares of land, 460 of which are vineyards, and a total production of about 4 million bottles per year. Angelini Holding is also present in the Baby food sector, in joint venture with the Hero Group through the company MadreNatura, which offers 100% organic baby food.

www.angeliniholding.it

Contacts

Angelini Group:

Alessandra Favilli - External Relations Director

alessandra.favilli@angeliniholding.com 

 

Angelini Pharma:

Daniela Poggio - Global Communications Head

daniela.poggio@angelinipharma.com